Teijin to launch home healthcare business in Europe

 
• By Zoë Dann

The Japanese company Teijin Pharma has established a 50:50 joint venture with the Spanish pharma company Laboratorios del Dr Esteve, to enter the home respiratory therapy market in Europe, beginning in Spain. The joint venture, Esteve Teijin Healthcare (ETH), will be established through Teijin's holding company in Europe, Teijin Holdings Netherlands. ETH will acquire Esteve's total stake in Oximeplus, a Spanish provider of home respiratory therapy services, accounting for 51% of the company's outstanding stock. The company is expected to be established by the end of January.

The Japanese company Teijin Pharma has established a 50:50 joint venture with the Spanish pharma company Laboratorios del Dr Esteve, to enter the home respiratory therapy market in Europe, beginning in Spain. The joint venture, Esteve Teijin Healthcare (ETH), will be established through Teijin's holding company in Europe, Teijin Holdings Netherlands. ETH will acquire Esteve's total stake in Oximeplus, a Spanish provider of home respiratory therapy services, accounting for 51% of the company's outstanding stock. The company is expected to be established by the end of January.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: US policies in spotlight at BIO; Lilly’s Verve acquisition; UroGen’s bladder cancer approval; Ireland’s biopharma talent; and Korea proposes new AI R&D project.

Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC

 
• By Joseph Haas, Lisa Takagi, Sushmita Panda, and Xu Hu

Axcelead/Lotte Biologics/Kanaph and NextCure/Simcere also unveil ADC-focused pacts, plus deals involving Avata/Oceanus, GSK/Bharat Biotech, Cullinan/Genrix and more.

Defying Gravity: Five Drugs That Surpassed Their Sales Forecasts

 
• By Edwin Elmhirst

Many assets outperform their pre-launch sales predictions despite the frequent overestimation of forecasts within the industry. In this article, Scrip highlights several such assets and the factors that influenced their predictions.

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

More from Scrip